Drugs / In vivo BCMA/GPRC5D Tandem Dual CAR-T cell
In vivo BCMA/GPRC5D Tandem Dual CAR-T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07586709 | May 2026 → Mar 2029 expected | plasma cell neoplasm | Liping Dou | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | In vivo BCMA/GPRC5D Tandem Dual CAR-T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07586709 ↗ |
| Modality | Cell therapy | “in vivo BCMA/GPRC5D-targeted CAR-T cell immunotherapy” NCT07586709 ↗ |